A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels

This study has been completed.
Sponsor:
Information provided by:
International Partnership for Microbicides, Inc.
ClinicalTrials.gov Identifier:
NCT00613249
First received: January 31, 2008
Last updated: March 26, 2009
Last verified: March 2009

January 31, 2008
March 26, 2009
November 2007
March 2008   (final data collection date for primary outcome measure)
  • Serial dapivirine concentrations in plasma, vaginal fluid and cervical-vaginal tissue samples [ Time Frame: 11 days ] [ Designated as safety issue: No ]
  • Self-reported genital symptoms, pelvic/colposcopic exam findings, laboratory evaluations and adverse events/serious adverse events [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00613249 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels
A Double-Blind, Randomized, Placebo-Controlled Phase I Study to Compare the Pharmacokinetics of Intravaginal Dapivirine Gel 4750, 0.05%, 2.5g and Dapivirine Gel 4789, 0.05%, 2.5g Formulations and to Assess the Safety as Compared to the Intravaginal HEC-Based Universal Placebo Gel, 2.5g in Healthy HIV-Negative Women.

IPM 012 is a double-blind, randomized, placebo-controlled phase I study conducted at one research center in Belgium among 36 healthy, HIV-negative women of 18-40 years of age, randomized in a 1:1:1 ratio to assess plasma, vaginal fluid and vaginal tissue levels and the pharmacokinetics of dapivirine when applying either Dapivirine Gel 4750, 0.05%, 2.5g or Dapivirine Gel 4789, 0.05%, 2.5g intravaginally for 11 days (1 day followed by a 3 day washout period and then 10 consecutive days); and to assess the safety of these gels as compared to the intravaginal HEC-based universal placebo gel.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
HIV Infections
  • Drug: Dapivirine Gel 4750, 0.05%, 2.5g
    intravaginal gel, dosed daily
  • Drug: Dapivirine Gel 4789, 0.05%, 2.5g
    intravaginal gel, dosed daily
  • Drug: HEC-based Placebo Gel
    intravaginal gel, dosed daily
  • Experimental: A
    Intervention: Drug: Dapivirine Gel 4750, 0.05%, 2.5g
  • Experimental: B
    Intervention: Drug: Dapivirine Gel 4789, 0.05%, 2.5g
  • Placebo Comparator: C
    Intervention: Drug: HEC-based Placebo Gel
Nel A, Smythe S, Habibi S, Romano J. 2009. Comparison of Safety and PK of Two Formulations of Dapivirine Vaginal Gel in Healthy, HIV-Negative Women [abstract]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal. Available from: http://www.retroconference.org/2009/PDFs/1065.pdf

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
March 2008
March 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women between 18 and 40 years of age, inclusive
  • Willing and able to give written informed consent
  • Available for all visits and consent to follow all procedures
  • Healthy, based on medical history, vital signs, physical examination, urinalysis, laboratory evaluations for genital infections and laboratory evaluations for hematology, liver and renal function
  • HIV-negative as determined by a HIV-1 ELISA test at enrollment
  • Willing to abstain from sexual activity for the duration of the study
  • On stable oral contraceptive regimen for 2 months prior to enrollment and willing to continue
  • Upon pelvic/speculum examination, the cervix and vagina appear normal
  • Willing to refrain from the use of vaginal products from 14 days prior to enrollment and for the duration of the study

Exclusion Criteria:

  • History of alcoholism, drug abuse, psychosis, antagonistic personality, poor motivation or other emotional or intellectual problems that are likely to invalidate the informed consent process or adversely impact adherence with protocol requirements
  • History of sensitivity/allergy to any component of the study product or to latex
  • Currently pregnant or breast-feeing, or within 3 months of last pregnancy outcome
  • Currently or within one month of participating in any other clinical research study
  • History or current diagnosis and/or treatment for a STD within the last three months prior to enrollment
  • Current vulvar, vaginal or cervical symptoms/abnormalities as determined by pelvic/speculum exam or colposcopy that could influence the study results
  • History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding or urethral obstruction within the last 3 months
  • Current non-iatrogenic pelvic/colposcopic exam findings involving deep epithelial disruption
  • Smoking more than 10 cigarettes a day
Female
18 Years to 40 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT00613249
IPM 012
No
Dr. Annalene Nel, International Partnership for Microbicides
International Partnership for Microbicides, Inc.
Not Provided
Study Director: Dr. Annalene Nel IPM
International Partnership for Microbicides, Inc.
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP